Summit Therapeutics Inc. (SMMT) Down 5.5% — Should I Scale Back Here?
Summit Therapeutics Inc. (SMMT) is under pressure on Thursday, last trading at $16.96 on the NASDAQ — down $0.99 from the prior close of $17.95. That leaves the stock roughly 42.0% below its 52-week high of $29.23, reached on April 21, 2026, though still about 40.5% above the bottom of its 52-week range at $12.07. The stock sits in the middle of a wide band, and today's decline erases much of the ground gained earlier this month.
Volume is light so far. About 1.63 million shares have traded against a 90-day average of roughly 6.02 million, or about 27% of normal turnover with the session still underway. The selling is steady but not heavy.
Why Summit Therapeutics Inc. Price is Moving Lower
Today's decline looks specific to Summit rather than part of a Health Care-wide retreat. The SPDR S&P Biotech ETF (XBI) was trading at $150.38, essentially flat against its previous close of $150.23. Broader indexes were down modestly as Brent crude topped $104 and Treasury yields held near multidecade highs. Peer moves were uneven. Revolution Medicines, Inc. (RVMD) slid 9.23% while Moderna, Inc. (MRNA) was nearly unchanged, down 0.09%, which points to stock-by-stock repositioning rather than a coordinated sector exit.
The most plausible explanation is a pullback after a strong run, with the share-supply overhang from the AstraZeneca (AZN) deal adding pressure. On October 2, Summit announced a trial collaboration with AstraZeneca and Daiichi Sankyo to test ivonescimab alongside Datroway, starting with a planned Phase III trial in first-line triple-negative breast cancer, and the stock gained about 7.3% that day. Three days later, on October 5, AstraZeneca completed its $2 billion equity investment. The deal consists of approximately 108,955 preferred shares, convertible into about 109 million common shares at $18.36 each. That gives AstraZeneca rights to roughly 12% of outstanding shares, or about 10.6% on a fully diluted basis.
The capital strengthens Summit's ability to fund development, but it also adds potential share supply. With SMMT now trading below the $18.36 conversion price, the dilution question has moved from theoretical to tangible.
The calendar adds to the caution. The FDA's target decision date for ivonescimab is November 14, 2026, a binary event that can push investors to cut exposure ahead of the outcome. The fundamental backdrop offers little cushion. Second-quarter EPS came in at -$0.28 against a -$0.27 consensus estimate, a narrow miss. The GAAP net loss did narrow sharply year over year to $215.7 million from $565.7 million, but Summit remains a heavily loss-making company whose valuation depends almost entirely on a single regulatory and commercial outcome.
What is the Summit Therapeutics Inc. Rating - Should I Sell?
Weiss Ratings assigns SMMT a D- rating. The rating was upgraded on 8/12/2025. Current recommendation is Sell. The upgrade lifted Summit off the lowest rungs of the scale. However, the D- rating still reflects a company whose financial profile has not caught up with the scientific enthusiasm around its lead asset. A $13.81 billion market cap built on a drug that has not yet cleared the FDA carries a risk profile that Weiss's framework does not reward.
The clearest strength is the Excellent rating on the Solvency Index. AstraZeneca's $2 billion investment, completed just days ago, gives Summit a funding base that few development-stage biotechs can match. It sharply reduces the near-term risk of a distressed capital raise ahead of a potential launch. The Fair rating on the Total Return Index rests on the stock's climb from its 52-week low of $12.07 to today's $16.96. That rating stops at Fair because shares remain about 42% below the April peak of $29.23, so holders who bought near the highs are still well underwater.
Where the picture turns decisively is in the operating metrics. The Very Weak ratings on both the Growth Index and the Efficiency Index reflect a business that has yet to build a commercial revenue base. Summit is still absorbing large losses, with EPS of -$1.12 and a forward P/E of -15.43, which shows profitability is not expected in the near term. The Weak rating on the Volatility Index follows the same thread. A 7.3% one-day gain on the AstraZeneca and Daiichi Sankyo collaboration, followed by a 5.51% retreat a week later as the dilution overhang and FDA timeline come into focus, is the kind of swing that keeps this dimension from being rated higher.
Within the Health Care sector, Summit Therapeutics sits alongside Moderna, Inc. (MRNA, D-), Natera, Inc. (NTRA, D-), and Roivant Sciences Ltd. (ROIV, D-). It trails Zoetis Inc. (ZTS, D), whose established animal health business gives it a modestly better profile. None of these names offers a compelling risk/reward case in Weiss's framework, and Summit's dependence on a single asset makes its position among them especially fragile.
About Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) is a Health Care company focused on discovering, developing, and commercializing medicines designed to serve patients, physicians, caregivers, and society. Founded in 2003 and headquartered in Miami, Florida, the company has concentrated its resources on one lead development candidate, ivonescimab. It is a bispecific antibody that combines PD-1 immune checkpoint blockade with anti-angiogenesis activity in a single molecule, aimed at non-small cell lung cancer and colorectal cancer.
Ivonescimab is being studied in combination with chemotherapy in Phase III trials across three settings. These are patients with epidermal growth factor receptor-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer, first-line metastatic non-small cell lung cancer, and first-line unresectable metastatic colorectal cancer. The October 2026 collaboration with AstraZeneca and Daiichi Sankyo extends that program further. It pairs ivonescimab with Datroway in a planned Phase III trial in first-line triple-negative breast cancer, which would move the antibody beyond its initial lung and colorectal focus.
Summit's competitive case rests on the dual-mechanism design of ivonescimab, which aims to combine two established oncology approaches in one therapy, and on strategic backing from AstraZeneca as both investor and development partner. The company's commercial footprint spans the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa. Its concentration on a single asset means its fortunes are closely tied to ivonescimab's clinical and regulatory progress.
Investor Outlook
Summit Therapeutics Inc. (SMMT) carries a Weiss Rating of D- (Sell), and today's pullback shows how much uncertainty remains priced into a stock that depends on one drug. The FDA's November 14 decision date for ivonescimab is the dominant near-term event. Investors should also watch how shares trade relative to AstraZeneca's $18.36 conversion price and whether Summit can begin narrowing its losses as a commercial-stage company. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--